Israel Englander Biocryst Pharmaceuticals Inc Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 1,751,561 shares of BCRX stock, worth $14.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,751,561

Previous 201,200 770.56%

Holding current value

$14.8 Million

Previous $1.02 Million 959.1%

% of portfolio

0.01%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $324,651 - $533,748	-78,608 Reduced 4.3%	1,751,561 $10.8 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $752,996 - $1.18 Million	153,987 Added 9.19%	1,830,169 $9.3 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $18.1 Million - $24.5 Million	-3,625,838 Reduced 68.39%	1,676,182 $10 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $6.02 Million - $7.62 Million	864,691 Added 19.49%	5,302,020 $37.3 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $35.1 Million - $52.4 Million	4,421,538 Added 28000.37%	4,437,329 $37 Million
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $13.8 Million - $18.6 Million	-1,310,651 Reduced 98.81%	15,791 $181,000
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $6.71 Million - $9.21 Million	-622,153 Reduced 31.93%	1,326,442 $16.7 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $14.9 Million - $33.9 Million	1,893,640 Added 3445.8%	1,948,595 $20.6 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $703,761 - $1.2 Million	-60,879 Reduced 52.56%	54,955 $894,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $3.42 Million - $4.73 Million	-306,019 Reduced 72.54%	115,834 $1.6 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $4.17 Million - $5.18 Million	-293,287 Reduced 41.01%	421,853 $6.06 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $4.07 Million - $7.39 Million	428,508 Added 149.5%	715,140 $11.3 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $10.5 Million - $26.8 Million	-3,107,280 Reduced 91.55%	286,632 $2.14 Million
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $10.9 Million - $17.5 Million	-3,171,629 Reduced 48.31%	3,393,912 $11.7 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $215,080 - $635,052	113,200 Added 1.75%	6,565,541 $31.3 Million
Q1 2020 May 14, 2020	SELL	$1.6 - $4.11 $5.58 Million - $14.3 Million	-3,488,336 Reduced 35.09%	6,452,341 $12.9 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $3.46 Million - $7.51 Million	2,177,342 Added 28.05%	9,940,677 $34.3 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $1.67 Million - $2.49 Million	667,038 Added 9.4%	7,763,335 $22.2 Million
Q2 2019 Aug 15, 2019	BUY	$2.91 - $9.15 $16.1 Million - $50.7 Million	5,539,512 Added 355.83%	7,096,297 $26.9 Million
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $5.53 Million - $7.28 Million	748,758 Added 92.66%	1,556,785 $12.7 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $2.42 Million - $3.57 Million	-371,780 Reduced 31.51%	808,027 $6.52 Million
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $2.85 Million - $4.12 Million	-515,526 Reduced 30.41%	1,179,807 $9 Million
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $4.58 Million - $6.49 Million	-994,922 Reduced 36.98%	1,695,333 $9.71 Million
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $4.43 Million - $5.93 Million	-1,019,287 Reduced 27.48%	2,690,255 $12.8 Million
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $193,951 - $248,500	-46,623 Reduced 1.24%	3,709,542 $18.2 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $15.4 Million - $22.4 Million	3,756,165	3,756,165 $19.7 Million

Others Institutions Holding BCRX

# of Institutions

257

Shares Held

173M

Call Options Held

397K

Put Options Held

444K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account